New Data Show Drug Extended Survival In Breast Cancer Patients | Beaufort County Now | A drug called Enhertu reportedly extended survival of advanced breast cancer patients by more than six months, according to new data sets disclosed this past weekend.

Coronavirus Disease 2019 (COVID-19)
    Publisher's Note: This post appears here courtesy of the The Daily Wire. The author of this post is Amanda Prestigiacomo.

    A drug called Enhertu reportedly extended survival of advanced breast cancer patients by more than six months, according to new data sets disclosed this past weekend.

    The promising data was revealed Sunday at an American Society of Clinical Oncology meeting in Chicago.

    "That really puts a lot of confidence that the benefit that we're seeing here is absolutely real," said David Fredrickson, executive vice president of pharmaceutical company AstraZeneca's oncology unit, Reuters reported.

    AstraZeneca, along with pharmaceutical company Daiichi Sankyo, developed the drug, which is administered to patients as an intravenous infusion.

    "The ongoing phase III trial involves over 550 patients with so-called HER2-low breast cancer - most with tumours that were hormone-sensitive - whose disease had spread and had undergone at least one round of chemotherapy," the report outlined. "The interim analysis showed Enhertu prolonged survival by an additional 6.4 months in patients with hormone-sensitive tumours. Patients in the group lived for a median of 23.9 months versus 17.5 months for chemotherapy."

    "In the small group of patients with hormone-insensitive tumours, patients on Enhertu lived 6.3 months longer," Reuters added.

    Enhertu "has been linked to a type of lung scarring called interstitial lung disease (ILD)," the report warned. "Forty-five Enhertu patients in the trial had varying degrees of ILD versus one in the chemotherapy group."

    The drug is currently being "evaluated for use in earlier stages of breast cancer, as well as lung and colorectal cancers, among others. It has secured approval in HER2-driven gastric cancer," Reuters said.

    "As far as breast cancer goes, I'd say at least in the next few years, I'm pretty sure in Enhertu is going to kind of finish revolutionising the treatment paradigm," said Informa Pharma Custom Intelligence's Tara Hansen.

    On the same day the Enhertu data sets were revealed, a paper outlining results from a small cancer trial that left every patient in remission was published at The New England Journal of Medicine, The Daily Wire reported.

    The paper outlined a study of 18 rectal cancer patients who were given dostarlimab every three weeks for six months and ended up cancer-free, including the first patient who is now two years out from the trial.

    "I believe this is the first time this has happened in the history of cancer," said Dr. Luis A. Diaz Jr. said, an author of the paper, The New York Times reported.

    Dr. Andrea Cercek, an oncologist at Memorial Sloan Kettering Cancer Center and another author of the paper, described "a lot of happy tears" at the end of the trial.

    While noting the study needs replication, Dr. Kimmie Ng, a colorectal cancer expert from Dana-Farber Cancer Institute, called the trial results "remarkable" and "unprecedented."

    "We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti-PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair-deficient stage II or III rectal adenocarcinoma," the study said. "This treatment was to be followed by standard chemoradiotherapy and surgery."

    Those who took the drug, which "unmasks cancer cells, allowing the immune system to identify and destroy them," according to the Times, did not have to move on to further cancer treatments.

    All the patients "had a clinical complete response, with no evidence of tumor on magnetic resonance imaging," the paper explained. "At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported."

    The Daily Wire is one of America's fastest growing conservative media companies for breaking news, investigative reporting, sports, podcasts, in-depth analysis, books, and entertainment for a reason: because we believe in what we do. We believe in our country, in the value of truth and the freedom to speak it, and in the right to challenge tyranny wherever we see it. Believe the same? Become a member now and join our mission.
Go Back

HbAD0

Latest Op-Ed & Politics

Have you heard the latest? Uncle Joe is attempting to appropriate billions of dollars to a program designed to mandate that CRT is taught across the nation in OUR public schools.
Saule Omarova, Democrat President Joe Biden’s nominee for comptroller of the currency, has withdrawn her name from consideration for the position after facing increasing opposition to nomination over allegations that she was a Marxist.
The Federal Reserve announced an increase in interest rates Wednesday afternoon, boosting the cost of borrowing money by 0.75%, the largest increase in a single meeting in nearly 30 years.
Clarence Thomas tells us what we need to be working toward
Politicians in Washington are growing increasingly nervous, as the CDC has announced they have discovered the first case of Lizardpox on American shores.
Treasury Secretary Janet Yellen said on Sunday that suspending gas taxes is “certainly worth considering” amid rising energy prices.

HbAD1

Australia reportedly will not send officials to the 2022 Winter Olympics in Beijing, China, in response to the communist nation’s genocide against religious minorities.
To what extent can a selective educational institution advantage certain racial groups in admissions decisions without discriminating against other groups simultaneously?
Treasury Secretary Janet Yellen on Sunday blamed global factors for Americans’ spiraling purchasing power and declared a recession is “not at all inevitable,” despite a growing consensus the U.S. could soon find out one is already underway.
With the price of food skyrocketing and the value of Bitcoin plummeting, McDonald's restaurants across the world have rolled out a new value menu in which all items cost only 1 Bitcoin.
Sen. Ted Cruz (R-TX) slammed President Joe Biden during a speech on the Senate floor Tuesday over the unfolding crisis in Ukraine. Tens of thousands of Russian soldiers have been amassing near its border in what experts warn might be a prelude to an invasion.
The North Carolina State Health Plan and the National Academy for State Health Policy Find that North Carolina's Dominant Hospital Systems Recorded Billions of Dollars in Profits After Taking Taxpayer-Funded COVID Relief

HbAD2

Governor Ron DeSantis (R-FL) got some unexpected praise late this week from media personality Bill Maher, who insisted that DeSantis would be better than former President Donald Trump.

HbAD3

 
Back to Top